On-line solid-phase extraction LC-MS/MS for the determination of Ac-SDKP peptide in human plasma from hemodialysis patients

Biomedical Chromatography

Volumn 26, Issue 2, 2012, Pages 137-141

  Inoue, Koichi ^a   Ikemura, Ayaka ^a   Tsuruta, Yoshinari ^b   Tsutsumiuchi, Kaname ^c   Hino, Tomoaki ^a   Oka, Hisao ^a  

^a KINJO GAKUIN UNIVERSITY   (Japan)

^b Meiyo Clinic   (Japan)

^c CHUBU UNIVERSITY   (Japan)

Author keywords

Hemodialyzed subjects; Human plasma; Liquid chromatography tandem mass spectrometry (LC MS MS); N acetyl seryl aspartyl lysyl proline (Ac SDKP); On line solid phase extraction

Indexed keywords

DIALYSIS; DIRECT INJECTION; ELECTROSPRAY IONIZATION; EXTRACTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHASE SEPARATION; PLASMA (HUMAN);

CHRONIC KIDNEY DISEASE; HEMODIALYSIS PATIENT; HEMODIALYZED SUBJECT; HUMAN PLASMAS; LC-MS-MS; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (LC-MS/MS); LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; N ACETYLS; N-ACETYL-SERYL-ASPARTYL-LYSYL-PROLINE (AC-SDKP); ON-LINE SOLID PHASE EXTRACTION;

PEPTIDES;

SERASPENIDE;

ARTICLE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; HEMODIALYSIS PATIENT; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; ONLINE SOLID PHASE EXTRACTION; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

EID: 83755228516     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1636     Document Type: Article

References (17)

1. Azizi M, Ezan E, Nicolet L, Grognet JM and Ménard J. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 1997; 30: 1015-1019.
2. Azizi M, Ménard J, Peyrard S, Lièvre M, Marre M and Chatellier G. Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study. Diabetes Care 2006; 29: 1331-1336.
3. Carvasin MA, Rhaleb NE, Yang XP and Carretero OA. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 2004; 43: 1140-1145.
4. FDA. Guidance for Industry. Bioanalytical Method Validation. US Department of Health and Human Services, FDA, CDER and CVM, 2001; available from:.
5. Guigon M and Bonnet D. Inhibitory peptides in hematopoiesis. Experimental Hematology 1995; 23: 477-481.
6. Hannappel E. Thymosin beta4 and its posttranslational modifications. Annals of the New York Academy of Sciences 2010; 1194: 27-35.
7. Inoue K, Ikemura A, Tsuruta Y, Watanabe K, Tsutsumiuchi K, Hino T and Oka H. Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2011; 54: 765-771.
8. Johansen KL, Finkelstein FO, Revicki DA, Gitlin M, Evans C and Mayne TJ. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. American Journal of Kidney Diseases 2010; 55: 535-548.
9. Junot C, Theodoro F, Thierry J, Clement G, Wdzieczak-Bakala J and Ezan E. Development of an enzyme immunoassay for a stable amidated analog of the hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro. Journal of Immunoassay & Immunochemistry 2001a; 22: 15-31.
10. Junot C, Pruvost A, Créminon C, Grognet JM, Benech H and Ezan E. Characterization of immunoreactive acetyl-Ser-Asp-Lys-Pro in human plasma and urine by liquid chromatography-electrospray mass spectrometry. Journal of Chromatography B 2001b; 752: 69-75.
11. Le Meur Y, Lorgeot V, Comte L, Szelag JC, Aldigier JC, Leroux-Robert C, Praloran V. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. American Journal of Kidney Diseases 2001; 38: 510-517.
12. Liozon E, Pradelles P, Venot J, Rigaud M, Cransac M, Bordessoule D and Frindel E. Serum levels of a negative regulator of cell proliferation (AcSDKP) are increased in certain human haemopathies. Leukemia 1993; 7L 808-812.
13. Liu JM, Garcia-Alvarez MC, Bignon J, Kusinski M, Kuzdak K, Riches A and Wdzieczak-Bakala J. Overexpression of the natural tetrapeptide acetyl-N-ser-asp-lys-pro derived from thymosin beta4 in neoplastic diseases. Annals of the New York Academy of Sciences 2010; 1194: 53-59.
14. Nolte WM, Tagore DM, Lane WS and Saghatelian A. Peptidomics of prolyl endopeptidase in the central nervous system. Biochemistry 2009; 48: 11971-11981.
15. Pradelles P, Frobert Y, Créminon C, Liozon E, Massé A and Frindel E. Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochemical and Biophysical Research Communications 1990; 170: 986-993.
16. Sosne G, Qiu P, Goldstein AL and Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. The FASEB Journal 2010; 24: 2144-2451.
17. van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA and van Gilst WH. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 2005; 112: 1743-1747.